ホーム>>Signaling Pathways>> PI3K/Akt/mTOR Signaling>> Akt>>K-80003 (TX-803)

K-80003 (TX-803) (Synonyms: TX-803)

カタログ番号GC33357

K-80003 (TX-803) は、tRXRα 依存性の Akt 活性化とがん細胞増殖の強力な阻害剤です。

Products are for research use only. Not for human use. We do not sell to patients.

K-80003 (TX-803) 化学構造

Cas No.: 1292821-90-9

サイズ 価格 在庫数 個数
5mg
$125.00
在庫あり
10mg
$179.00
在庫あり
25mg
$396.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com


顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

K-80003 is a potent inhibitor of tRXRα-dependent Akt activation and cancer cell growth.

When MCF-7 cells are cotreated with K-80003, TNFα-induced colocalization of tRXRα with p85α in the cytoplasm is inhibited, resulting in tRXRα nuclear localization. Western blotting shows that K-80003-stabilized tetrameric form of tRXRα is found exclusively in the nuclear fraction, while tRXRα monomer is distributed both in the nuclear and cytoplasmic fractions[2].

K-80003 is a potent inhibitor of AKT activation by all-trans-retinoic acid. K-80003 displays enhanced efficacy in inhibiting tRXRα-dependent AKT activation and tRXRα tumor growth in animals. K-80003 has high affinity to RXRα but lacks COX inhibitory activity[1].

[1]. Zhou H, et al. NSAID sulindac and its analog bind RXRalpha and inhibit RXRalpha-dependent AKT signaling. Cancer Cell. 2010 Jun 15;17(6):560-73. [2]. Chen L, et al. Modulation of nongenomic activation of PI3K signalling by tetramerization of N-terminally-cleaved RXRα. Nat Commun. 2017 Jul 17;8:16066.

レビュー

Review for K-80003 (TX-803)

Average Rating: 5 ★★★★★ (Based on Reviews and 40 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for K-80003 (TX-803)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.